Assistant Professor, Medicine, Stanford University School of Medicine
Oncology
Dr. Arash Alizadeh, MD
|
|
Give Review
Arash Alizadeh is an expert in the field of Oncology. He researched medicine at Stanford University School of Medicine. Stanford University School of Medicine is one of the top medical schools in the US. Stanford University School of Medicine is ranked 2/25 in Research/PrimaryCare. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Arash Alizadeh, MD is also a published doctor. He has 69 paper published. The most recent paper is: Probing lymphocyte biology by genomic-scale gene expression analysis. Dr. Arash Alizadeh accepts Medicare.
Publications
- Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic Cell transplantation.
- Utility in prognostic value added by molecular profiles for diffuse large B-Cell lymphoma.
- Rituximab use and survival after diffuse large B-Cell or follicular lymphoma: a population-based study.
- Hierarchy in somatic mutations arising during genomic evolution and progression of follicular Lymphoma.
- High PD-1 expression and suppressed cytokine signaling distinguish T Cells infiltrating follicular lymphoma tumors from peripheral T Cells.
- Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.
- Self-antigen recognition by follicular lymphoma B-Cell receptors.
- Role of Smad proteins in resistance to BMP-induced growth inhibition in B-Cell lymphoma.
- Absolute lymphocyte count at day 28 independently predicts event-free and oVerall survival in adults with newly diagnosed acute lymphoblastic leukemia.
- CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas: Diagnostic and Therapeutic Implications.
- The chemoattractant chemerin suppresses melanoma by recruiting natural killer Cell antitumor defenses.
- Specific post-translational histone modifications of neutrophil extraCellular traps as immunogens and potential targets of lupus autoantibodies.
- A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle Cell lymphoma.
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid Tumors.
- First isolation of Cryptococcus uzbekistanensis from an immunocompromised patient with Lymphoma.
- Three differentiation states risk-stratify bladder Cancer into distinct subtypes.
- Treatment advances have not improved the early death rate in acute promyelocytic leukemia.
- A few good genes: simple, biologically motivated signatures for Cancer prognosis.
- A proteomic approach for the identification of novel lysine methyltransferase substrates.
- Utility of positron emission tomography scans in mantle Cell lymphoma.
- Surprise! HSC are aberrant in chronic lymphocytic leukemia.
- Prediction of survival in diffuse large B-Cell lymphoma based on the expression of two genes reflecting tumor and microenvironment.
- Prospective separation of normal and leukemic stem Cells based on differential expression of TIM3, a human acute myeloid leukemia stem Cell marker.
- CD137 stimulation enhances the antiLymphoma activity of anti-CD20 antibodies.
- Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.
- Association of a leukemic stem Cell gene expression signature with clinical outcomes in acute myeloid leukemia.
- Calreticulin is the dominant pro-phagocytic signal on multiple human Cancers and is counterbalanced by CD47.
- Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
- Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin Lymphoma.
- B-Cell signaling networks reveal a negative prognostic human lymphoma Cell subset that emerges during tumor progression.
- Expression profiles of adult T-Cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha.
- Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2).
- Therapeutic effect of CD137 immunomodulation in Lymphoma and its enhancement by Treg depletion.
- A pluripotency signature predicts histologic transformation and influences survival in follicular Lymphoma patients.
- CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem Cells.
- Molecular outcome prediction in diffuse large-B-Cell lymphoma.
- Evaluation and management of angioimmunoblastic T-Cell lymphoma: a review of current approaches and future strategies.
- Double trouble in follicular Lymphoma: A rare and unusual synergy of oncogenes in the germinal center.
- Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray.
- Cell-type specific gene expression profiles of leukocytes in human peripheral blood.
- Distinct IL-4-induced gene expression, proliferation, and intraCellular signaling in germinal center B-Cell-like and activated B-Cell-like diffuse large-Cell lymphomas.
- AID is expressed in germinal center B-Cell-like and activated B-Cell-like diffuse large-Cell lymphomas and is not correlated with intraclonal heterogeneity.
- Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
- Prediction of survival in diffuse large-B-Cell lymphoma based on the expression of six genes.
- Gene expression signature of fibroblast serum response predicts human Cancer progression: similarities between tumors and wounds.
- T cell receptor-independent Basal signaling via Erk and Abl kinases suppresses RAG gene expression.
- Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock.
- Rheumatoid arthritis is a heterogeneous Disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues.
- Transformation of follicular lymphoma to diffuse large Cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations.
- Individuality and variation in gene expression patterns in human blood.
- SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data.
- HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-Cell lymphoma.
- Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays.
- Genomic expression programs and the integration of the CD28 costimulatory signal in T Cell activation.
- Transformation of follicular lymphoma to diffuse large-Cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes.
- The t(14;18) defines a unique subset of diffuse large B-Cell lymphoma with a germinal center B-Cell gene expression profile.
- In vivo regulation of human skeletal muscle gene expression by thyroid hormone.
- Stereotyped and specific gene expression programs in human innate immune responses to bacteria.
- Towards a novel classification of human Malignancies based on gene expression patterns.
- Genomic analysis of Renal allograft dysfunction using cDNA microarrays.
- The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and Malignant lymphocytes.
- 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.
- Ongoing immunoglobulin somatic mutation in germinal center B Cell-like but not in activated B Cell-like diffuse large Cell lymphomas.
- Genomic-scale gene expression profiling of normal and malignant immune Cells.
- Examining the living genome in health and Disease with DNA microarrays.
- Distinct types of diffuse large B-Cell lymphoma identified by gene expression profiling.
- Genome-wide analysis of DNA copy-number changes using cDNA microarrays.
- Probing lymphocyte biology by genomic-scale gene expression analysis.
Schools
Stanford University
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Stanford University -
Stanford University School of Medicine
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1295824423 | |
| NPPES Provider LastName | ALIZADEH | |
| NPPES Provider FirstName | ARASH | |
| NPPES Provider ZIPCode | 943055101 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 137.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1295824423 |
| Last Name Of The Provider | ALIZADEH |
| First Name Of The Provider | ARASH |
| View All |
Similar Doctors
|
|
Dr. Robert Kessler, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bertil Glader, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melinda L. Telli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anosheh Afghahi, MD |
|
|
Dr. Pamela L. Kunz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Leibowitz, MD |
|
|
Dr. Barbara T. Egan, MD |
|
|
Dr. Mary-Elizabeth M. Percival, MD |
|
|
Dr. Ina P. Rhee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley L. Schrier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Myron M. Turbow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert D. Stebbins, MD |
|
|
Dr. Gail Wright, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Priya Chakravarthi, MD |
|
|
Dr. Frank E. Stockdale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander D. Colevas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann M. Lowe, MD |
|
|
Dr. Beverly S. Mitchell, MD
This Doctor is OpenDoctor Recommended.
|